Abstract
The KLF6 is a zinc-finger tumor suppressor that is frequently mutated in several human cancers and broadly involved in differentiation and development, growth-related signal transduction, cell proliferation, apoptosis, and angiogenesis. To determine whether genetic alterations of KLF6 gene are involved in the development and/or progression of gastric cancer, we have screened a set of 80 sporadic gastric cancers for mutations and allele loss of the KLF6 gene. Four missense mutations, S155R, P172 T, S180L, and R198 K, were detected in transactivation domain of the KLF6 gene and one of them had biallelic mutations with somatic mutation of one allele and loss of the remaining allele. All of the cases with mutation were of advanced intestinal-type gastric cancer with lymph node metastasis. In addition, 16 (43.2%) of 37 informative cases showed allelic loss at KLF6 locus. Interestingly, allelic loss was also frequent in intestinal-type gastric cancer. Therefore, our data suggest that genetic alterations of KLF6 gene might play an important role in the development or progression of sporadic gastric cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Benzeno S, Narla G, Allina J, Cheng GZ, Reeves HL, Banck MS, Odin JA, Diehl JA, Germain D and Friedman SL . (2004). Cancer Res., 64, 3885–3891.
Bieker JJ . (2001). J. Biol. Chem., 276, 34355–34358.
Black AR, Black JD and Azizkhan-Clifford J . (2001). J. Cell. Physiol., 188, 143–160.
Chen C, Hyytinen E-R, Sun X, Helin HJ, Koivisto PA, Frierson Jr HF, Vessella RL and Dong J-T . (2003). Am. J. Pathol., 162, 1349–1354.
Clements WM, Wang J, Sarnaik A, Kim OJ, MacDonald J, Fenoglio-Preiser C, Groden J and Lowy AM . (2002). Cancer Res., 62, 3503–3506.
Fodde R and Smits R . (2002). Science, 298, 761.
Hiyama T, Tanaka S, Shima H, Kose K, Kitadai Y, Ito M, Sumii M, Yoshihara M, Shimamoto F, Haruma K and Chayama K . (2003). Oncol Rep., 10, 1297–1299.
Ito G, Uchiyama M, Kondo M, Mori S, Usami N, Maeda O, Kawabe T, Hasegawa Y, Shimokata K and Sekido Y . (2004). Cancer Res., 64, 3838–3843.
Jeng Y-M and Hsu H-C . (2003). Int. J. Cancer, 105, 625–629.
Kremer-Tal S, Reeves HI, Narla G, Thung SN, Schwartz M, Difel A, Katz A, Bruix J, Bioulac-Sage P, Martignetti JA and Friedman SL . (2004). Hepatology, 40, 1047–1052.
Lee JY, Dong SM, Kim SY, Yoo NJ, Lee SH and Park WS . (1998). Virchows Arch., 433, 305–309.
Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC, Glucksman MJ, Narla J, Eng FJ, Chan AM, Ferrari AC, Martignetti JA and Friedman SL . (2001). Science, 294, 2563–2566.
Nishizuka S, Tamura G, Terashima M and Satodate R . (1998). J. Pathol., 185, 38–43.
Onyango P, Koritschoner NP, Patriot LC, Zenke M and Weith A . (1998). Genomics, 48, 143–144.
Parkin DM, Pisanin P and Ferlay J . (1993). Int. J. Cancer, 54, 594–606.
Reeves HL, Narla G, OgunbiYi O, Haq AI, Katz A, Benzeno S, Hod E, Harpaz N, Goldberg S, Tal-Kremer S, Eng FJ, Arthur MJ, Martignetti JA and Friedman SL . (2004). Gastroenterology, 126, 1090–1103.
Sheffield VC, Beck JS, Kwitek AE, Sandstrom DW and Stone EM . (1993). Genomics, 16, 325–332.
Suh CI, Suh K-A, Park S-H, Chang HJ, Ko J-W and Ahn D-H . (2000). J. Korean Cancer Assoc., 32, 827–834.
Tamura G, Sakata K, Nishizuka S, Maesawa C, Suzuki Y, Terashima M, Eda Y and Satodate R . (1996). J. Pathol., 180, 371–377.
Yamashita K, Upadhyay S, Osada M, Hoque MO, Xiao Y, Mori M, Sato F, Meltzer SJ and Sidransky D . (2002). Cancer Cell, 2, 485–495.
Yustein AS, Harper JC, Petroni GR, Cummings OW, Moskaluk CA and Powell SM . (1999). Cancer Res., 59, 1437–1441.
Acknowledgements
This work was supported by the Korea Science & Engineering Foundation (KOSEF) through the Cell Death Disease Research Center at The Catholic University of Korea.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Cho, Y., Kim, C., Park, C. et al. Genetic alterations of the KLF6 gene in gastric cancer. Oncogene 24, 4588–4590 (2005). https://doi.org/10.1038/sj.onc.1208670
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208670
Keywords
This article is cited by
-
Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation
Apoptosis (2016)
-
MicroRNA-181a promotes gastric cancer by negatively regulating tumor suppressor KLF6
Tumor Biology (2012)
-
A small interfering RNA targeting the KLF6 splice variant, KLF6-SV1, as gene therapy for gastric cancer
Gastric Cancer (2011)
-
The Influence of Methylated Septin 9 Gene on RNA and Protein Level in Colorectal Cancer
Pathology & Oncology Research (2011)
-
Decreased expression of KLF6 and its significance in gastric carcinoma
Medical Oncology (2010)